Allarity Therapeutics, Inc. Secures Japan Patent for Stenoparib DRP to 2039
Allarity Therapeutics received a Japanese patent for its stenoparib-specific DRP companion diagnostic, with protection into 2039. The patent covers methods to predict benefit from stenoparib and to select patients using the DRP test.Material DetailsContext by AI AnalystThis is an IP expansion step…